Liquidia Corporation
LQDA
株式のランク
#4826
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
株価
$36.39
時価総額
$3.26B
変化（1日）
5.94%
変化（1年）
61.88%
国
US
取引 Liquidia Corporation (LQDA)
カテゴリー
Healthcare
Liquidia Corporation（LQDA）のEPS
June 2026 時点のEPS TTM: $1.57
Liquidia Corporationの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$1.57です。2023年末には、EPSは$-1.21で、2022年のEPS$-0.67と増加でした。
Liquidia CorporationのEPS履歴（2016から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $1.57 | -194.58% |
| 2024 | $-1.66 | 37.19% |
| 2023 | $-1.21 | 80.60% |
| 2022 | $-0.67 | -4.29% |
| 2021 | $-0.70 | -60.23% |
| 2020 | $-1.76 | -29.88% |
| 2019 | $-2.51 | -66.17% |
| 2018 | $-7.42 | 118.24% |
| 2017 | $-3.40 | 82.80% |
| 2016 | $-1.86 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $2.41 | 53.50% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -66.88% |
US
|
